Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease

PA Yates; R Sirisriro; VL Villemagne; S Farquharson; CL Masters; CC Rowe

Journal article

Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease

PA Yates, R Sirisriro, VL Villemagne, S Farquharson, CL Masters, CC Rowe

Neurology | Published : 2011

DOI: 10.1212/WNL.0b013e318221ad36

Abstract

Objectives: Incidental cerebral microhemorrhage (MH) is frequently found in older individuals scanned with susceptibility-weighted MRI (SWI) or gradient-recalled echo MRI. MH have been linked with β-amyloid (Aβ) deposition using 11C-Pittsburgh compound B (PiB) PET in Alzheimer disease (AD) and cerebral amyloid angiopathy (CAA). We hypothesized that Aβ deposition in asymptomatic elderly individuals is associated with lobar MH (LMH). Methods: This was a cross-sectional study of 84 elderly healthy controls (HC), 28 subjects with mild cognitive impairment (MCI), and 26 subjects with probable AD who underwent 3-T SWI and 11C-PiB PET. 11C-PiB cortical binding was quantified normalized to cerebella..

View full abstract

University of Melbourne Researchers

Paul Andrew Yates Author

Victor Villemagne Author

Christopher Rowe Author

Grants

Funding Acknowledgements

Dr. Yates has received a research scholarship from the Commonwealth Government Dementia Collaborative Research Centres (Early Diagnosis and Prevention). Dr. Sirisriro reports no disclosures. Dr. Villemagne serves as on a scientific advisory board and as a consultant for Bayer Schering Pharma; serves as Associate Editor for the Journal of Alzheimer's Disease; and has received research support from the Commonwealth Scientific and Industrial Research Organisation (CSIRO). S. Farquharson and Prof. Masters report no disclosures. Prof. Rowe serves on scientific advisory boards for Bayer Schering Pharma, Elan Corporation, AstraZeneca, and GE Healthcare; has received speaker honoraria from Bayer Schering Pharma; has received research support from Bayer Schering Pharma, Avid Radiopharmaceuticals, Inc., Alzheimer's Association, and the Alzheimer's Drug Discovery Foundation; and his department has received funding from CSIRO, as a sponsor of AIBL, for PiB, and MRI scans. Supported by CSIRO and National Health and Medical Research Council Dementia Collaborative Research Centres Early Diagnosis and Prevention Program.